Zydus Lifesciences on Monday said it has received approval from US health regulator USFDA to market a generic antifungal medication to treat dandruff, fungal infections, and other skin conditions.
The company has received final approval from the US Food and Drug Administration to manufacture Ketoconazole Shampoo, 2 pc, it said in a statement.
Ketoconazole shampoo is an antifungal medication used to treat dandruff, fungal infections, and other skin conditions.
The product will be produced at the Zydus Group's topical manufacturing site at Changodar, Ahmedabad.
As per IQVIA MAT January 2025 data, Ketoconazole shampoo had annual sales of $68.89 mn in the US.
Shares of Zydus Lifesciences were trading 0.22% up at Rs 903.10 apiece on BSE.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
